EUVIMEDEUVIMED entdecken
Crossref

Weight change and impact on prognosis in patients with advanced non-small cell lung cancer with concomitant diabetes mellitus treated with sglt2 inhibitors

Noboru Morikawa, Tateaki Naito, Yuta Okawa, Suguru Matsuda, Meiko Morita, Motoki Sekikawa, Kosei Doshita, Michitoshi Yabe, Hiroaki Kodama, Keita Miura, Yuko Iida, Nobuaki Mamesaya und 6 weitere

Supportive Care in Cancer · 2026-05 · 34 (5)

DOI: 10.1007/s00520-026-10709-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, online erschienen am 28.04.2026. Verfasst von Noboru Morikawa und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Oncology, Shizuoka Cancer Center Hospital, 1007 Shimonagakubo Nagaizumi-Cho Sunto-Gun, Shizuoka, 411-8777, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Sodium-Glucose Transporter 2 Inhibitors, Weight Loss, Lung Neoplasms. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are commonly used to manage diabetes and are known to cause weight loss. This study aimed to clarify whether SGLT2i-induced weight loss influences survival or toxicity during systemic therapy in patients with advanced non-small cell lung cancer (NSCLC) and comorbid diabetes. METHODS: We conducted a retrospective analysis of patients with advanced NSCLC and diabetes who received first-line systemic therapy. Patients with an Eastern Cooperative Oncology Group performance status (PS) ≥ 3, driver mutations, interstitial lung disease, untreated diabetes, or missing data were excluded. We compared weight changes, progression-free survival (PFS), overall survival (OS), and adverse events between patients with and without SGLT2i. We defined cachexia as either 5% or more body-weight loss within six months prior to the initiation of lung cancer treatment or weight loss greater than 2% and a body-mass index (BMI) of less than 20 kg/m2. RESULTS: Eighteen patients (21.9%) out of 82 received SGLT2i for diabetes. There was no difference in the incidence of cachexia between the two groups (66.7% vs. 46.9%, p = 0.184), despite significant weight loss in the SGLT2 group compared to the non-SGLT2 group (median - 5.8% vs. - 3.4%, p = 0.039). No significant differences were observed in progression-free survival (PFS) (median 6.2 vs. 4.1 months, p = 0.512) or overall survival (OS) (median 11.9 vs. 14.6 months, p = 0.583). Grade ≥ 3 adverse events occurred in 11.1% of patients in the SGLT2i group and 31.2% of patients in the non-SGLT2i group (P = 0.132). There were no cases of diabetic ketoacidosis or urinary tract infections. CONCLUSION: SGLT2 inhibitors were associated with weight loss and were not associated with worse survival or increased toxicity in this limited retrospective cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungSodium-Glucose Transporter 2 InhibitorsWeight LossLung NeoplasmsDiabetes MellitusDiabetes Mellitus, Type 2HumansRetrospective StudiesFemaleMaleMiddle AgedAgedPrognosisCachexiaProgression-Free SurvivalAged, 80 and overSurvival RateBody Mass Index

Stichwörter der Autor:innen

CachexiaDiabetes mellitusNSCLCSGLT2iWeight loss

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Division of Thoracic Oncology, Shizuoka Cancer Center Hospital, 1007 Shimonagakubo Nagaizumi-Cho Sunto-Gun, Shizuoka, 411-8777, Japan.
  • Division of Respiratory Medicine, Chutoen General Medical Center, Shizuoka, Japan.
  • Division of Thoracic Oncology, Shizuoka Cancer Center Hospital, 1007 Shimonagakubo Nagaizumi-Cho Sunto-Gun, Shizuoka, 411-8777, Japan. t.naito@scchr.jp.
  • Cancer Supportive Care Center, Shizuoka Cancer Center, Shizuoka, Japan. t.naito@scchr.jp.
  • Division of Endocrinology and Metabolism, Shizuoka Cancer Center, Shizuoka, Japan.

Zitieren

APA

Morikawa, N., Naito, T., Okawa, Y., Matsuda, S., Morita, M., Sekikawa, M., Doshita, K., Yabe, M., Kodama, H., Miura, K., Iida, Y., Mamesaya, N., Kobayashi, H., Ko, R., Ono, A., Kenmotsu, H., Murakami, H., & Takahashi, T. (2026). Weight change and impact on prognosis in patients with advanced non-small cell lung cancer with concomitant diabetes mellitus treated with sglt2 inhibitors. Supportive Care in Cancer, 34(5). https://doi.org/10.1007/s00520-026-10709-8

Vancouver

Morikawa N, Naito T, Okawa Y, Matsuda S, Morita M, Sekikawa M, et al. Weight change and impact on prognosis in patients with advanced non-small cell lung cancer with concomitant diabetes mellitus treated with sglt2 inhibitors. Supportive Care in Cancer. 2026;34(5). doi:10.1007/s00520-026-10709-8

BibTeX
@article{Morikawa2026,
  author = {Morikawa, Noboru and Naito, Tateaki and Okawa, Yuta and Matsuda, Suguru and Morita, Meiko and Sekikawa, Motoki and Doshita, Kosei and Yabe, Michitoshi and Kodama, Hiroaki and Miura, Keita and Iida, Yuko and Mamesaya, Nobuaki and Kobayashi, Haruki and Ko, Ryo and Ono, Akira and Kenmotsu, Hirotsugu and Murakami, Haruyasu and Takahashi, Toshiaki},
  title = {Weight change and impact on prognosis in patients with advanced non-small cell lung cancer with concomitant diabetes mellitus treated with sglt2 inhibitors},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {5},
  doi = {10.1007/s00520-026-10709-8}
}
Kostenlos starten →